News

ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million
ABVC's Oncology Licensing to OncoX Highlights Scalable Royalty Strategy SILICON VALLEY, CA - June 6, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage ...
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the ...
Kalkine Media6h
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum
Matinas BioPharma, Inc. (NYSE:MTNB) operates in the clinical-stage biopharmaceutical sector and is listed on the  NYSE ...
Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) ...
Crain's Chicago Business2d
Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug
XP 8121 is a combination drug meant to better control hypothyroidism, in part by moving its common therapy, levothyroxine, ...
Fierce Pharma1d
Fujifilm, Coherus, ViGeneron unveil rebrands to better reflect ongoing work
After a long winter, the start of summer is ushering in some much-needed sunshine, warmer weather and, for a handful of ...
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial
The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...
Sanofi to buy US biopharma group Blueprint for over $9 billion
France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...
Aytu BioPharma, Inc.: Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the ...